This is preserved historical wording.
It is no longer the current profile. Read the canonical profile and its correction notice.
It is no longer the current profile. Read the canonical profile and its correction notice.
Correction · September 15, 2026
We clarified that CJC-1295 with DAC is a related, distinct active moiety rather than an interchangeable form. The FDA briefing describes five bulk substances; clinical findings must retain the studied form. 3
What this version reported
FDA's 2024 briefing distinguishes five bulk substances and reports that none is a component of an FDA-approved drug. Evidence for a DAC-modified substance cannot automatically establish effects for a non-DAC form.↗
Organizations named in cited records:
- U.S. Food and Drug Administration↗
Sources for this version
- 1Certain bulk drug substances for use in compounding that may present significant safety risks ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 2Nicholasville Compounding Pharmacy and Its Owner Plead Guilty to Unlawful Distribution of Prescription Drugs ↗
U.S. Department of Justice · Official source · Source checked July 22, 2026
- 3FDA evaluation of five CJC-1295-related bulk substances, November 15, 2024 ↗
U.S. Food and Drug Administration · Official source · Source checked September 15, 2026